Thermo Fisher Scientific announces to start construction of a new $35 million state-of-the-art pharma services supply chain facility in Rheinfelden (Baden) Germany. 

The facility expands Thermo Fisher’s footprint in the European Union. The new facility will feature the latest technology and modern infrastructure to significantly increase European capacity for cold and ambient clinical trial materials in support of complex clinical research and so meet the growing needs of customers. The facility will be scalable for mixed-use space and provide a strategic logistical location for shipping either by road or air. 

Construction of the 8,000 square meter facility is expected to take 12 to 18 months. Once complete, this new facility will provide up to 200 new jobs locally. The investment includes the option for additional expansion with the potential for doubling the footprint. 

The company’s decision to expand is in response to a growing demand for global clinical supply services, worldwide. The new facility will also serve to address GDP guidelines, Clinical Trial Regulations Annex 6 and the new Falsified Medicines Directive 2019. This GMP/GDP facility builds on the company’s existing footprint of 20 purpose-built cGMP facilities globally.